• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lyell Immunopharma, Inc. - Common Stock (NQ: LYEL )

    0.6497 +0.0368 (+6.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Lyell Immunopharma, Inc. - Common Stock

    < Previous 1 2 Next >
    Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Completes Acquisition of ImmPACT Bio
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Announces Participation in September Investor Conferences
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma to Participate in BofA Securities Health Care Conference
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Announces Participation in March Investor Conferences
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
    Six presentations highlight innovations designed to shorten TIL manufacturing, new nonclinical data on LYL119, new technologies and clinical trials in progress 
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progress 
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
    From Lyell Immunopharma, Inc; Cellares
    Via GlobeNewswire
    Lyell Immunopharma to Participate in Upcoming Investor Conferences
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.